GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Aduro Biotech Inc (NAS:ADRO) » Definitions » Current Ratio

Aduro Biotech (Aduro Biotech) Current Ratio : 8.91 (As of Jun. 2020)


View and export this data going back to 2015. Start your Free Trial

What is Aduro Biotech Current Ratio?

The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Aduro Biotech's current ratio for the quarter that ended in Jun. 2020 was 8.91.

Aduro Biotech has a current ratio of 8.91. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.

The historical rank and industry rank for Aduro Biotech's Current Ratio or its related term are showing as below:

ADRO's Current Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 3.77
* Ranked among companies with meaningful Current Ratio only.

Aduro Biotech Current Ratio Historical Data

The historical data trend for Aduro Biotech's Current Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Aduro Biotech Current Ratio Chart

Aduro Biotech Annual Data
Trend Dec13 Dec14 Dec15 Dec16 Dec17 Dec18 Dec19
Current Ratio
Get a 7-Day Free Trial 13.66 11.58 8.46 9.27 10.09

Aduro Biotech Quarterly Data
Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17 Sep17 Dec17 Mar18 Jun18 Sep18 Dec18 Mar19 Jun19 Sep19 Dec19 Mar20 Jun20
Current Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 8.45 7.26 10.09 9.13 8.91

Competitive Comparison of Aduro Biotech's Current Ratio

For the Biotechnology subindustry, Aduro Biotech's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Aduro Biotech's Current Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Aduro Biotech's Current Ratio distribution charts can be found below:

* The bar in red indicates where Aduro Biotech's Current Ratio falls into.



Aduro Biotech Current Ratio Calculation

The current ratio is mainly used to give an idea of the company's ability to pay back its short-term liabilities with its short-term assets.

Aduro Biotech's Current Ratio for the fiscal year that ended in Dec. 2019 is calculated as

Current Ratio (A: Dec. 2019 )=Total Current Assets (A: Dec. 2019 )/Total Current Liabilities (A: Dec. 2019 )
=217.902/21.601
=10.09

Aduro Biotech's Current Ratio for the quarter that ended in Jun. 2020 is calculated as

Current Ratio (Q: Jun. 2020 )=Total Current Assets (Q: Jun. 2020 )/Total Current Liabilities (Q: Jun. 2020 )
=180.98/20.303
=8.91

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Aduro Biotech  (NAS:ADRO) Current Ratio Explanation

The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.

Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.

The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.

If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.


Aduro Biotech Current Ratio Related Terms

Thank you for viewing the detailed overview of Aduro Biotech's Current Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Aduro Biotech (Aduro Biotech) Business Description

Traded in Other Exchanges
N/A
Address
740 Heinz Avenue, Berkeley, CA, USA, 94710
Aduro Biotech Inc is a immunotherapy company focused on the discovery, development and commercialization of therapies that are designed to harness the body's natural immune system for the treatment of patients with challenging diseases. Its primary technologies related are to the Stimulator of Interferon Genes (STING) and A Proliferation Inducing Ligand. The STING pathway activator technology is designed to activate the intracellular STING receptor. The APRIL is a soluble factor that binds to BCMA and TACI receptors thereby inducing signaling, and is implicated in IgA nephropathy.
Executives
Michelle Renee Griffin director 19723 NE 65TH LANE, KIRKLAND WA 98033
William Mariner Greenman director C/O CERUS CORPORATION, 2411 STANWELL DRIVE, CONCORD CA 94520
Ross Haghighat director C/O ADURO BIOTECH, INC., 626 BANCROFT WAY, 3C, BERKELEY CA 94710
Dolca Thomas director C/O PRINCIPIA BIOPHARMA INC., 220 E. GRAND AVENUE, SOUTH SAN FRANCISCO CA 94080
Srinivas Akkaraju director 565 EVERETT AVENUE, PALO ALTO CA 94301
Tom Frohlich officer: Chief Business Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Eric Dobmeier director, officer: President, CEO C/O SAETTLE GENETICS INC, 21823 30TH DRIVE SE, BOTHELL WA 98021
Davis Jerel director ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Voyageurs I Parallel, L.p. 10 percent owner ONE SANSOME STREET, SUITE 3630, SAN FRANCISCO CA 94104
Versant Venture Capital Vii, L.p. 10 percent owner ONE SANSOME STREET, SUITE 1650, SAN FRANCISCO CA 94104
Andrew James King officer: Head of Renal Discovery C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Alan Glicklich officer: Chief Medical Officer C/O CHINOOK THERAPEUTICS U.S., INC., 1600 FAIRVIEW AVE. E., SEATTLE WA 98102
Celeste Ferber officer: SVP, GC and Secretary C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710
Blaine Templeman officer: Chief Legal Officer C/O ADURO BIOTECH, INC., 740 HEINZ AVENUE, BERKELEY CA 94710

Aduro Biotech (Aduro Biotech) Headlines

From GuruFocus

Aduro Biotech Announces Corporate Restructuring

By Marketwired Marketwired 01-10-2020